| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Teruhiko Higuchi, Jun Ishigooka, Masaomi Iyo, Chin-Bin Yeh, Esther Gunaseli Ebenezer, Kuei Yu Liang, Jung Sik Lee, Sang Yeol Lee, Shih Ku Lin, Bo-Hyun Yoon, Masatoshi Nakamura, Katsuhiko Hagi, Takayuki Sat. Lurasidone in the treatment of schizophrenia: Results of a double-blind, placebo-controlled trial in Asian patients. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists. vol 11. issue 2. 2019-12-17. PMID:30950208. |
lurasidone in the treatment of schizophrenia: results of a double-blind, placebo-controlled trial in asian patients. |
2019-12-17 |
2023-08-13 |
Not clear |
| Teruhiko Higuchi, Jun Ishigooka, Masaomi Iyo, Chin-Bin Yeh, Esther Gunaseli Ebenezer, Kuei Yu Liang, Jung Sik Lee, Sang Yeol Lee, Shih Ku Lin, Bo-Hyun Yoon, Masatoshi Nakamura, Katsuhiko Hagi, Takayuki Sat. Lurasidone in the treatment of schizophrenia: Results of a double-blind, placebo-controlled trial in Asian patients. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists. vol 11. issue 2. 2019-12-17. PMID:30950208. |
to evaluate efficacy and safety of lurasidone for the treatment of asian patients with schizophrenia. |
2019-12-17 |
2023-08-13 |
Not clear |
| Wei Zheng, Dong-Bin Cai, Xin-Hu Yang, Lu Li, Qing-E Zhang, Chee H Ng, Gabor S Ungvari, Xian-Bin Li, Yu-Ping Ning, Yu-Tao Xian. Corrigendum to "Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials" [J. Psychiatr. Res. 103 (2018) 244-251]. Journal of psychiatric research. vol 105. 2019-11-20. PMID:30149220. |
corrigendum to "short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: a meta-analysis of randomized controlled trials" [j. psychiatr. |
2019-11-20 |
2023-08-13 |
Not clear |
| Daisy Ng-Mak, Vanita Tongbram, Kerigo Ndirangu, Krithika Rajagopalan, Antony Loebe. Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis. Journal of comparative effectiveness research. vol 7. issue 8. 2019-11-01. PMID:29697278. |
efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis. |
2019-11-01 |
2023-08-13 |
Not clear |
| Wei Zheng, Dong-Bin Cai, Xin-Hu Yang, Lu Li, Qing-E Zhang, Chee H Ng, Gabor S Ungvari, Xian-Bin Li, Yu-Ping Ning, Yu-Tao Xian. Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials. Journal of psychiatric research. vol 103. 2019-09-03. PMID:29906709. |
short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: a meta-analysis of randomized controlled trials. |
2019-09-03 |
2023-08-13 |
Not clear |
| Jiang Li, Antony Loebel, Herbert Y Meltze. Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: A meta-analysis of samples from three independent clinical trials. Schizophrenia research. vol 199. 2019-03-11. PMID:29730043. |
a genome-wide association study (gwas) of response of schizophrenia patients to the atypical antipsychotic drug, lurasidone, based on two double-blind registration trials, identified snps from four classes of genes as predictors of efficacy, but none were genome wide significant (gws). |
2019-03-11 |
2023-08-13 |
Not clear |
| Mei Huang, Sunoh Kwon, Lakshmi Rajagopal, Wenqi He, Herbert Y Meltze. 5-HT Psychopharmacology. vol 235. issue 10. 2018-12-31. PMID:30066135. |
5-ht the effect of atypical antipsychotic drugs (aapds), e.g., lurasidone, to improve cognitive impairment associated with schizophrenia (cias), has been suggested to be due, in part, to enhancing release of dopamine (da), acetylcholine (ach), and glutamate (glu) in cortex and hippocampus. |
2018-12-31 |
2023-08-13 |
Not clear |
| Seth C Hopkins, Ajay Ogirala, Antony Loebel, Kenneth S Kobla. Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia. Schizophrenia bulletin. vol 44. issue 3. 2018-12-11. PMID:28981857. |
we then used the upsm to transform panss in data from 4657 unique schizophrenia patients included in 12 additional lurasidone clinical trials. |
2018-12-11 |
2023-08-13 |
Not clear |
| John W Newcomer, Daisy Ng-Mak, Krithika Rajagopalan, Antony Loebe. Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis. BMC health services research. vol 18. issue 1. 2018-12-11. PMID:29618351. |
hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a us claims database analysis. |
2018-12-11 |
2023-08-13 |
Not clear |
| John W Newcomer, Daisy Ng-Mak, Krithika Rajagopalan, Antony Loebe. Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis. BMC health services research. vol 18. issue 1. 2018-12-11. PMID:29618351. |
this study compared hospital admission rates among adult patients with schizophrenia who switched to antipsychotic monotherapy with lurasidone or quetiapine. |
2018-12-11 |
2023-08-13 |
Not clear |
| Jiang Li, Akane Yoshikawa, Mark D Brennan, Timothy L Ramsey, Herbert Y Meltze. Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes. Schizophrenia research. vol 192. 2018-10-31. PMID:28431800. |
genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes. |
2018-10-31 |
2023-08-13 |
Not clear |
| Jiang Li, Akane Yoshikawa, Mark D Brennan, Timothy L Ramsey, Herbert Y Meltze. Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes. Schizophrenia research. vol 192. 2018-10-31. PMID:28431800. |
we sought to identify common variants in genes which predict response to lurasidone, an aapd, by associating genome-wide association study (gwas) data and changes (Δ) in positive and negative syndrome scale (panss) scores from two 6-week randomized, placebo-controlled trials of lurasidone in schizophrenia (scz) patients. |
2018-10-31 |
2023-08-13 |
Not clear |
| Robert Goldman, Antony Loebel, Josephine Cucchiaro, Ling Deng, Robert L Findlin. Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study. Journal of child and adolescent psychopharmacology. vol 27. issue 6. 2018-07-11. PMID:28475373. |
efficacy and safety of lurasidone in adolescents with schizophrenia: a 6-week, randomized placebo-controlled study. |
2018-07-11 |
2023-08-13 |
Not clear |
| Robert Goldman, Antony Loebel, Josephine Cucchiaro, Ling Deng, Robert L Findlin. Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study. Journal of child and adolescent psychopharmacology. vol 27. issue 6. 2018-07-11. PMID:28475373. |
to evaluate the efficacy and safety of lurasidone in acutely symptomatic adolescent patients with schizophrenia. |
2018-07-11 |
2023-08-13 |
Not clear |
| Michael H Allen, Leslie Citrome, Andrei Pikalov, Jay Hsu, Antony Loebe. Efficacy of lurasidone in the treatment of agitation: A post hoc analysis of five short-term studies in acutely ill patients with schizophrenia. General hospital psychiatry. vol 47. 2018-05-07. PMID:28807142. |
efficacy of lurasidone in the treatment of agitation: a post hoc analysis of five short-term studies in acutely ill patients with schizophrenia. |
2018-05-07 |
2023-08-13 |
Not clear |
| Michael H Allen, Leslie Citrome, Andrei Pikalov, Jay Hsu, Antony Loebe. Efficacy of lurasidone in the treatment of agitation: A post hoc analysis of five short-term studies in acutely ill patients with schizophrenia. General hospital psychiatry. vol 47. 2018-05-07. PMID:28807142. |
this post hoc analysis evaluated the effect of lurasidone on agitation in acutely ill patients with schizophrenia. |
2018-05-07 |
2023-08-13 |
Not clear |
| Jaime M Monti, Pablo Torterolo, Seithikurippu R Pandi Peruma. The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia. Sleep medicine reviews. vol 33. 2018-04-24. PMID:27321864. |
to date, no polysomnographic studies have been published on the effects of aripiprazole, asenapine, iloperidone and lurasidone on sleep in either healthy subjects or patients with schizophrenia. |
2018-04-24 |
2023-08-13 |
human |
| Maurizio Pompili, Claudio Verzura, Giada Trovini, Andrea Buscajoni, Giulia Falcone, Stefano Naim, Adele Nardella, Serena Sorice, Ross J Baldessarini, Paolo Girard. Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders. Expert opinion on drug safety. vol 17. issue 2. 2018-02-15. PMID:28902525. |
lurasidone has regulatory approval for treatment of undefined duration in schizophrenia. |
2018-02-15 |
2023-08-13 |
Not clear |
| Qi Zheng, Bangshan Liu, Shuyin Xu, Mei Liao, Yan Zhang, Lingjiang L. [Research progress in mechanisms and clinical application for blonanserin and lurasidone in improving cognitive function of schizophrenia]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences. vol 42. issue 4. 2017-12-22. PMID:28490709. |
[research progress in mechanisms and clinical application for blonanserin and lurasidone in improving cognitive function of schizophrenia]. |
2017-12-22 |
2023-08-13 |
Not clear |
| Qi Zheng, Bangshan Liu, Shuyin Xu, Mei Liao, Yan Zhang, Lingjiang L. [Research progress in mechanisms and clinical application for blonanserin and lurasidone in improving cognitive function of schizophrenia]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences. vol 42. issue 4. 2017-12-22. PMID:28490709. |
recent studies indicated that two new atypical antipsychotics, blonanserin and lurasidone, are expected to improve the cognitive impairment in patients with schizophrenia. |
2017-12-22 |
2023-08-13 |
Not clear |